Unique Contributions of an Arginine Side Chain to Ligand Recognition in a Glutamate-gated Chloride Channel

Timothy Lynagh, Vitaly V. Komnatnyy, and Stephan A. Pless

From the Center for Biopharmaceuticals, Department of Drug Design and Pharmacology, University of Copenhagen, 2100 H Copenhagen, Denmark

Edited by F. Anne Stephenson

Glutamate recognition by neurotransmitter receptors often relies on Arg residues in the binding site, leading to the assumption that charge-charge interactions underlie ligand recognition. However, assessing the precise chemical contribution of Arg side chains to protein function and pharmacology has proven to be exceedingly difficult in such large and complex proteins. Using the in vivo nonsense suppression approach, we report the first successful incorporation of the isosteric, titratable Arg analog, canavanine, into a neurotransmitter receptor in a living cell, utilizing a glutamate-gated chloride channel from the nematode *Haemonchus contortus*. Our data unveil a surprisingly small contribution of charge at a conserved Arg side chain previously suggested to form a salt bridge with the ligand, glutamate. Instead, our data show that Arg contributes crucially to ligand sensitivity via a hydrogen bond network, where Arg interacts both with agonist and with a conserved Thr side chain within the receptor. Together, this data provide a new explanation for the reliance of neurotransmitter receptors on Arg side chains and highlights the exceptional capacity of unnatural amino acid incorporation for increasing our understanding of ligand recognition.

Neurotransmitter receptors are vital signaling proteins that are embedded in the cell membrane and trigger intracellular changes in response to extracellular chemical signals. The two classical receptor types are metabotropic, G-protein-coupled receptors (GPCRs) that act over seconds or minutes via intracellular second messengers (1), and ionotropic, ligand-gated receptors (LGICs) that act over milliseconds or microseconds (2). The rapid chemo-electric signaling of LGICs is perfectly suited to the nervous system, where activation of sodium channels and chloride channels mediates excitatory and inhibitory signals, respectively (2). The first step in the process of activation is the recognition of a specific ligand, which in the case of the animal nervous system is very often the neurotransmitter glutamate (3).

Glutamate binding to neurotransmitter receptors has been studied in great detail, reflected in X-ray structures of ligand-receptor complexes of both LGICs (4, 5) and GPCRs (6). Perhaps surprisingly, each complex contains an Arg side chain in close proximity to at least one of the glutamate carboxylates, suggestive of ionic interactions between negatively charged carboxylate and positively charged guanidino groups. Reduced function upon Ala substitution confirms the importance of these Arg residues in glutamate recognition in each receptor subfamily (7–9), but despite this apparent functional evidence for a charge-charge interaction, replacing a large Arg side chain with a much smaller Ala side chain involves more physicochemical changes than merely removing a positive charge. As such, the precise contribution of highly conserved Arg side chains in ligand recognition remains unknown.

Here, we have sought experimental evidence for charge-charge interactions in ligand recognition, focusing on the AVR-14B glutamate-gated chloride channel (GluCl (10)). GluCls are invertebrate-specific members of the pentameric ligand-gated ion channel (pLGIC or “Cys-loop receptor”) family, sharing significant homology with vertebrate GABA and acetylcholine receptors and constituting an important antiparasitic drug target (11). Despite the fact that a *Caenorhabditis elegans* GluCl was the first eukaryotic pLGIC to be visualized by X-ray crystallography (5), the molecular basis for neurotransmitter recognition in GluCls has received little experimental interrogation, as compared with vertebrate homologs. It has recently been shown, however, that in GluCls, glutamate recognition involves interactions between aromatic residues on the principal face of the binding site with the glutamate amine (7), as well as interactions between Arg residues in the binding site with the glutamate carboxylate groups (12), as illustrated in supplemental Fig. S1. We replaced Arg176 in the glutamate binding site with a titratable amino acid, providing us with the unprecedented opportunity to test glutamate sensitivity when an isosteric side chain is present but charged or uncharged. The results indicate only a small role of positive charge and unveil another unique property of Arg side chains that contributes to glutamate sensitivity, namely the ability to form hydrogen bonds both with the agonist and with vicinal receptor side chains.

Received for publication, December 16, 2016, and in revised form, January 11, 2017 Published, JBC Papers in Press, January 17, 2017, DOI 10.1074/jbc.M116.772939

This article contains supplemental Fig. S1.

Author’s Choice—Final version free via Creative Commons CC-BY license.

□ This work was supported by the Center for Biopharmaceuticals (University of Copenhagen), the Carlsberg Foundation, the Lundbeck Foundation, and the Danish Council for Independent Research (Det Frie Forskningsråd). The authors declare that they have no conflicts of interest with the contents of this article.

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
Glutamate (NH₂)

IVM

Results

To test whether positive charge of Arg residues 76 and 95 is sufficient for glutamate recognition in the glutamate binding site of the AVR-14B GluCl, we replaced these individually with Lys via site-directed mutagenesis and measured glutamate-gated chloride currents with two electrode voltage clamp experiments (Fig. 1, A and B). Given the water-accessible location of these positions in GluCls (13) and the positive charge on Lys side chains in such environments (14), one would expect glutamate sensitivity of mutant receptors to reflect that of WT receptors if positive charge were the main contribution of these side chains. However, we observed that glutamate sensitivity was practically abolished at R76K and R95K mutants (Fig. 1B), suggesting that positive charge alone at these positions is not sufficient for high glutamate sensitivity.

Although Arg-to-Lys substitution largely retains side chain size and charge, it also involves the loss of two potentially hydrogen-bonding (H-bonding) nitrogen atoms (Fig. 2A), which could also underlie the loss of glutamate sensitivity we observed in R76K and R95K mutants. Assessing the precise contributions of charge or H-bonding of the Arg side chain to glutamate recognition would thus require substitution with an uncharged but otherwise isosteric analog. To this end, we sought to replace Arg⁷⁶ with the lysine analog, canavanine (Can), an isosteric Arg analog with a pKa of 7 (15) (Fig. 2A), reasoning that experiments at low and high pH would assay glutamate sensitivity when a single guanidino side chain is protonated or deprotonated, respectively. Site-specific incorporation of Can was achieved by the in vitro nonsense suppression method (16) (Fig. 2B). Successful incorporation of Can at position Arg⁷⁶ was evident in robust glutamate-gated currents through Can⁷⁶ receptors, but although currents were also observed for Can⁹⁵, these were not significantly greater than controls lacking Can (Fig. 2C; ΔGlu 18 ± 5 nA, n = 10; 4 ± 2 nA, n = 8). This made further characterization of Can⁹⁵ receptors difficult, and we chose not to investigate these further.

When we measured glutamate sensitivity of Can⁷⁶ receptors at pH 7.0, at which one would expect only ~50% of Can⁷⁶ side chains to be protonated, we were surprised to find that the EC₅₀ for activation by glutamate was 48 ± 7 μM (n = 6), and thus not

![Figure 1: Arg-Lys substitutions drastically reduce glutamate recognition. A, X-ray structure of GLC-1 GluCl (PDB 3RIF; gray shading, notional cell membrane). Magnified view shows glutamate binding site and selected amino acid side chains. These include GLC-1 arginine residues 37 and 56, which are labeled Arg⁴⁷ and Arg⁶⁵ to describe the equivalent residues from the AVR-14B GluCl used in the present study. B, left, example recordings of glutamate (Glu) and ivermectin (IVM, 1 μM) responses at oocytes expressing mutant AVR-14B GluCls (scale bars: x, 5 s; y, 2 μA). Activation by IVM, which binds elsewhere on the receptor, confirms cell surface expression in the absence of Glu-gated currents. Right, mean ± S.E. (n = 4–8) peak current responses to increasing concentrations of Glu, normalized to maximum Glu-gated current (WT) or maximum IVM-gated current (mutants).

![Figure 2: Incorporation of titratable arginine analog, canavanine. A, L-lysine (Lys), L-arginine (Arg), and L-canavanine (Can). B, graphic illustrating nonsense suppression of Arg⁷⁶UAG mRNA by co-injection of Can-ligated tRNA into Xenopus laevis oocytes (yellow/brown spheres). C, mean peak current amplitude (± S.E.) in response to 10 μM glutamate at oocytes injected with mRNA and tRNA + Can (n = 8–15, * p < 0.05; n.s., not significant, ANOVA). Inset shows example responses to 10 μM glutamate at oocytes (pH = 7) injected with indicated RNA combinations (scale bars: x, 5 s; y, 20 nA). D, example recordings of current responses to increasing concentrations of glutamate and mean ± S.E. peak current responses (n = 5–8; normalized to maximum glutamate-gated current) at Can⁷⁶ GluCls (Can⁷⁶). Scale bars: x, 10 s; y, 100 nA. E, left, glutamate-gated currents at oocytes expressing wild-type or Can⁷⁶ GluCls continuously perfused at pH 7.0 or 5.8, as indicated (scale bars: x, 30 s; y, 100 nA). Right, mean ± S.E. peak current responses to 30 μM glutamate, normalized to maximum glutamate-gated current (μAmax/μImax, n = 5–8; *, p < 0.05; ***, p < 0.001, Student’s t-test). Gray arrows illustrate inhibition of 30 μM glutamate-gated current. Can⁷⁶ pH 7.0 recording in E is repeated from D.
Arginine Side Chain in Ligand Recognition

### TABLE 1

Glutamate sensitivity of Can76 and Arg76 GluCls

<table>
<thead>
<tr>
<th></th>
<th>EC\textsubscript{50} (\textmu M)</th>
<th>I\textsubscript{max} (nA)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Can76</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH 7.0</td>
<td>48 ± 7</td>
<td>60 ± 40</td>
<td>6</td>
</tr>
<tr>
<td>pH 8.5</td>
<td>119 ± 11\textsuperscript{***}</td>
<td>214 ± 91</td>
<td>5</td>
</tr>
<tr>
<td>pH 9.2</td>
<td>118 ± 12\textsuperscript{***}</td>
<td>110 ± 27</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Arg76 (WT)</strong></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pH 7.0</td>
<td>41 ± 11</td>
<td>241 ± 51</td>
<td>8</td>
</tr>
<tr>
<td>pH 8.5</td>
<td>43 ± 5</td>
<td>170 ± 47</td>
<td>8</td>
</tr>
<tr>
<td>pH 9.2</td>
<td>57 ± 7</td>
<td>428 ± 91</td>
<td>7</td>
</tr>
</tbody>
</table>

\(\textsuperscript{***} p < 0.001\) as compared with pH 7.0 (ANOVA with Tukey’s post test).

\[\text{Can76:} \quad \text{Arg76 with citrulline, an analog in which one nitrogen is replaced by an oxygen and which is uncharged (19), via non-sense suppression, but this was not successful (data not shown). Thus, and although a complete titration could not be completed, our data show that in conditions in which theoretically only 50% of Can76 side chains carry a positive charge. Can76 receptors show very similar glutamate sensitivity to WT Arg76 receptors (Table 1). Perhaps more strikingly, upon deprotonation and loss of positive charge in Can76 receptors, a mere 2-fold reduction in glutamate sensitivity is observed. This is a modest reduction in agonist sensitivity as compared with the 10,000-fold reduction caused by R76N or even R76K mutations in this very receptor (12) (Fig. 1), raising the possibility that a more substantial contribution to glutamate binding derives from some property of the Arg (or, indeed, Can) side chain other than positive charge. Additionally, some of that contribution is presumably via H-bonds between Arg (or Can) γNH₂ group(s) and glutamate (Fig. 3A), we considered that the Arg εNH group could also be important. Indeed, we noticed in the GLC-1 GluCl-glutamate X-ray structure (Protein Data Bank (PDB) 3RIF (5)) that although not in direct contact with the bound agonist, the hydroxyl oxygen atom of a Thr residue (equivalent to Thr\textsuperscript{23} in the AVR-14B GluCl) is located in close (2.9 Å) proximity to the εNH of the Arg equivalent to Arg\textsuperscript{76} (Fig. 3A). If this potential H-bond were important for glutamate sensitivity, we reasoned that the T93S substitution should retain glutamate sensitivity, as Ser also possesses a β-hydroxy group. In contrast, Val is sterically similar to Thr but devoid of the hydroxyl, and mutant T93V receptors would be expected to show decreased glutamate sensitivity. Indeed, when we measured glutamate-gated currents at these mutants, T93V receptors showed drastically reduced glutamate sensitivity, barely responding to millimolar concentrations (Fig. 3, B and C). By contrast, T93S receptors showed a 370-fold increase in glutamate sensitivity as compared with WT (Fig. 3, B and C; Table 2), confirming that the hydroxyl at this position is required for regular (or increased) glutamate sensitivity, likely through an interaction with Arg\textsuperscript{76}. Seeking specific evidence for this interaction, we performed double mutant cycle analysis, according to which the T93S mutation should not restore high glutamate sensitivity on R76K mutant receptors because these WT residues are coupled and the effects of their mutation are not simply additive (20–22). In contrast, the combined effects of mutating independent residues are additive, and the T93S mutation might be expected to confer higher glutamate sensitivity on R95K receptors, as we do not expect coupling between these two residues. Indeed, double mutant T93S/R95K receptors responded to glutamate in a concentration range between T93S and R95K single mutants (Fig.
Glutamate sensitivity of WT and conventional mutants

Oocytes were injected with 10 ng of WT or mutant mRNA. ***, p < 0.001 as compared with WT (ANOVA with Tukey’s post test).

<table>
<thead>
<tr>
<th>EC_{50}^a μM</th>
<th>I_{max}^b μA</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>17 ± 3</td>
<td>5.0 ± 0.5</td>
</tr>
<tr>
<td>R76K</td>
<td>&gt;100 μM  **</td>
<td>0.10 ± 0.02</td>
</tr>
<tr>
<td>T93S</td>
<td>0.046 ± 0.011 ***</td>
<td>4.8 ± 0.7</td>
</tr>
<tr>
<td>R95K</td>
<td>&gt;100 μM  **</td>
<td>0.05 ± 0.01</td>
</tr>
<tr>
<td>R76K/T93S</td>
<td>&gt;100 μM  **</td>
<td>0.44 ± 0.09</td>
</tr>
<tr>
<td>R95K/T93S</td>
<td>530 ± 140</td>
<td>1.3 ± 0.4</td>
</tr>
</tbody>
</table>

* EC_{50} value was calculated by plotting current amplitude against glutamate concentration and fitting with Hill equation for experiments at individual oocytes and then averaged. Data are mean ± S.E.
* For certain mutants, saturation in the concentration-response relationship was not reached, up to 30 mM glutamate. EC_{50} values are therefore estimated to be well over 100 μM.

Discussion

Taken together, these results suggest that the positive charge of Arg^27 contributes little to glutamate binding in GluCls. Instead, our results show that two other aspects of the Arg side chain contribute to effective glutamate recognition. First, the data suggest that H-bonds between the Arg NH_2 group(s) and the agonist α-carboxylate are important, as conventional Asn and Lys mutations that remove this moiety of Arg are severely detrimental to glutamate recognition, whereas the non-canonical substitution of Can, which retains NH_2 groups, retains WT-like glutamate sensitivity. Second, the eNH of Arg appears to interact closely with a vicinal receptor hydroxyl side chain, the removal of which via Val substitution drastically reduces glutamate sensitivity. Based on available GluCl structures, this interaction is likely to stabilize Arg for its interaction(s) with the glutamate α-carboxylate (Fig. 3A). Notably, this Loop D hydroxyl side chain is highly conserved in GluCls that possess the Loop G Arg (Arg^76 in AVR-14B), which interacts with the glutamate α-carboxylate. By contrast, the Loop D hydroxyl is absent in GluCls where instead a Loop A Arg (on the opposing face of the binding site, equivalent to Q141 in AVR-14B) interacts with the glutamate α-carboxylate (Fig. 3A) (12).

Conventional mutagenesis is an indispensable tool for dissection of protein structure and function, but in fine-tuning the details of ligand recognition, it is limited by the numerous physicochemical changes involved in most substitutions (23). This is perhaps especially the case for Arg, where conventional analogs Lys and His are noticeably smaller and more frequently than Arg uncharged in physiological settings (14, 24). Previous attempts to circumvent the limitations of conventional mutagenesis by incorporating unnatural Arg analogs have been few (19, 25, 26) and arguably difficult (27). Our use of the in vivo nonsense suppression method was successful for one of the two positions tested, and despite limited efficiency (currents through Can^26 were substantially smaller than conventional mutant receptors; compare I_{max} in Tables 1 and 2), the data strongly support the notion of robust and specific Can incorporation in three ways. First, the level of nonspecific incorporation of endogenous amino acids, as inferred from the very low current levels upon co-injection of uncharged tRNA, was very low (Fig. 2C). Second, although all conventional replacements at position 76 tested here and elsewhere (7, 12) resulted in drastic losses in glutamate sensitivity, we found Can incorporation to yield WT-like glutamate sensitivity (at pH 7.0; Table 1). Lastly, and perhaps most significantly, we found the agonist sensitivity of Can^76 receptors to be titratable between pH 7.0 and 8.5, a property that would be highly unlikely in the event of endogenous amino acids incorporating into this position. We note here that in our hands the incorporation of Can was more successful than citrulline at positions 76 and 95. However, we cannot assess with certainty the reason for this difference, which could be due to ribosomal recognition of the charged tRNA, protein folding, or protein function.

In conclusion, Can incorporation, together with subsequent conventional mutagenesis, has unveiled crucial determinants of ligand recognition that had previously escaped identification. Our results suggest that the common occurrence of Arg residues in glutamate binding sites is related to the ability of Arg side chains to participate in H-bonds both with ligand and with vicinal receptor side chains simultaneously. Thus, the unique propensity of Arg for forming multiple H-bonds, as described previously in the context of intramolecular interactions in other protein families (28), seems to have been utilized by Glu-
Arginine Side Chain in Ligand Recognition

ArgCys for the specific functional requirements of ligand recognition. The results also complement work on tetrameric ionotropic glutamate receptors (iGluRs), regarding both the unique role of Arg and the occurrence of vicinal hydroxyl side chains that could stabilize binding site architecture. In NMDA-type iGluRs, for example, Lys substitution of the Arg residue that binds the ligand α-carboxylate abolishes glutamate sensitivity (29, 30), much like R76K and R95K substitutions in the GluCl. Remarkably, NMDA-type iGluRs also contain Ser and Thr residues, whose side chain hydroxyl oxygens are, similar to Thr93 in the GluCl, as close as 2.7 Å to other side chains that form the glutamate binding site (29, 31), and whose substitution for Ala drastically reduces glutamate sensitivity (29).

We present here, to our knowledge, the first example of Arg analog incorporation into membrane-bound receptors, and as such, these results describe an incisive approach to dissecting chemical interactions in a broad and therapeutically relevant family of membrane proteins. Interestingly, an H-bond network adjacent to the ligand binding site has been proposed for the structurally related glycine receptor (32), suggesting that stabilization of ligand binding by such H-bond networks could be a conserved feature of ligand recognition by pLGICs.

Experimental Procedures

Chemical Synthesis—All reagents were of analytical grade and were used directly as received. The reagents were purchased from Sigma-Aldrich, unless stated otherwise. LC-MS analyses of synthesized compounds were performed on a Waters ACQUITY ultra high performance liquid chromatography system. Eluents A (0.1% HCOOH in water (v/v)) and B (0.1% HCOOH in acetonitrile (v/v)) were used in a linear gradient (100% A to 100% B) in a run time of 2.5 at a flow rate of 0.6 ml/min.

Nvoc-Can(Nvoc)-OH—Nvoc-Can(Nvoc)-OH was synthesized according to the procedure used elsewhere (33). L-Cana

vanine (1-α-amino-γ-(guanidinoxy)-n-butyric acid, 50 mg of H-Can-OH) was suspended in 1,4-dioxane (5 ml) along with sodium bicarbonate (120 mg, 5 eq). The resulting mixture was cooled down on ice bath, and Nvoc-Cl (4,5-dimethoxy-2-nitrobenzyl chloroformate, 175 mg, 2,2 eq) was added in one portion. The reaction mixture was left stirring overnight. Water (5 ml) was added, the resulting mixture was extracted with ethyl acetate (3 × 10 ml), and the organic layer was discarded. The water layer was acidified with 1 M HCl to pH 4, and then the compound was extracted with ethyl acetate (3 × 20 ml), and the combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting yellow oil (32 mg) was used directly in the next step. ESI MS calculated for C25H31N6O15 (M+H)+ 655.18; found 655.2.

Nvoc-Can(Nvoc)-OCCH3CN—The compound from the previous step was dissolved in 1 ml of chloroacetonitrile, and triethylamine (145 μl, 1 mmol) was added. The reaction was stirred at room temperature overnight. Chloroacetonitrile was then removed in vacuo, and residual oil was dissolved in ethyl acetate (2 ml) and triturated with glass pipette. Precipitate of triethylamine hydrochloride was filtered off and washed with an additional portion of ethyl acetate (5 ml). Combined filtrate was concentrated under reduced pressure and dried overnight in vacuo. Obtained cyanomethyl ester (white to yellow solid, 36 mg) was used without further purification. ESI MS calculated for C27H42N5O15 (M+H)+ 694.20; found 694.1.

Nvoc-Can(Nvoc)-OpdCpA—pdCpA (5’-O-phosphoryl-2’-deoxycytidylyl-3’—5’)adenosine (GE Healthcare/Dharmacon, 10 mg) was suspended in 200 μl of dry N,N-dimethylformamide, and Nvoc-Can(Nvoc)-OCH3CN (20 mg) and then NButOA (10 mg) were added. The reaction was shaken at 37 °C until pdCpA was fully dissolved. Another portion (10 mg) of pdCpA was added, and the reaction was shaken at 37 °C until pdCpA was almost fully reacted (ultra performance liquid chromatography MS). 1 ml of ice-cold ether was added to the reaction mixture, and precipitate was collected by centrifugation. The residue was dissolved in 100 μl of acetonitrile and precipitated with additional 1 ml of ice-cold ether. White-to-yellow residue was dried in an N2 stream. The compound was purified by preparative reverse-phase HPLC on a C18 Phenomenex Luna column (250 × 20 mm, 5 μm, 100 Å) at an Agilent 1260 LC system equipped with a diode array UV detector and an evaporative light scattering detector. Eluents A (0.1% TFA in H2O (v/v)) and B (0.1% TFA in MeCN (v/v)) were used in a linear gradient (100% A to 100% B) in a run time of 20 min and with a flow rate of 20 ml/min. Fractions, containing UV signatures for both NVOC group and pdCpA, were collected, acetonitrile was removed in vacuo, and the resulting water solu

tion was lyophilized. The obtained residue (2.6 mg) was dissolved in DMSO (100 μl), and the final concentration was adjusted to 3 μM by adding an additional volume of DMSO. ESI MS calculated for C44H51N14O26P2 (M-H2O)− 1253.26, C44H50N14O26P2Na (M-H2O+Na)+ 1275.24, found 1253.3, 1275.3.

Expression of GluCl—All reagents were from Sigma-Aldrich, unless otherwise stated. The cDNA of the AVR-14B GluCl from Haemonchus contortus in the pT7TS vector (10) was used for site-directed mutagenesis with custom-designed primers (Eurofins Genomics) and PCR with PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies). cDNA was linearized with XbaI (New England Biolabs), and mRNAs were synthesized with the Ambion mMESSAGE mMACHINE T7 transcription kit (Thermo Fisher Scientific) and purified in RNeasy columns (Qiagen). For incorporation of Can, we used the nonsense suppression method, where aminocylated Tetrahymena thermophila tRNA (34) recognizing the amber stop codon UAG is co-injected into Xenopus laevis oocytes along with receptor mRNA containing a UAG codon. This has been possible with the t-3’ DNA strands (Integrated DNA Technologies), RNA synthesis with T7-Scribe transcription kit (T7), and purification with Chroma Spin DEPC-H2O columns (Clontech). Aminoacylation of tRNA with Nvoc-Can(Nvoc)-OpdCpA was performed in vitro using T4 DNA ligase (New England Biolabs), and aminocyl-tRNA was purified with phenol-chloroform extraction and ethanol precipitation, air-dried, and stored at −80 °C until use. Immediately before injection into oocytes, aminocyl-tRNA was resuspended in 1 μl of water, and Nvoc was removed by 50-s exposure to UV light (400-watt xenon lamp, Newport).

Oocytes from Xenopus laevis frogs (anesthetized in 0.3% tricaine, according to license 2014-15-0201-00031, approved by the Danish Veterinary and Food Administration) were sepa-
rated with forces and then treated with 0.5 mg/ml Type I collagenase (Worthington Biochemical) in OR2 (in mM, 2.5 NaCl, 2 KCl, 1 MgCl2, 5 HEPES, pH 7.4 with NaOH) with continuous shaking at 200 rpm and 37 °C. These were incubated in OR2 at 18 °C until injection of mRNA. For conventional mutants and WT mRNAs, 10 ng, in a volume of 40 nl (diluted in water), was injected using a Nanoliter 2010 injector (World Precision Instruments). For Can incorporation, 40 ng of UAG-mutant mRNA together with aminoacyl tRNA, in a volume of 40 nl, was injected. For lower expression of WT (Table 1), 0.04 ng mRNA was injected. Oocytes were incubated in Leibovitz’s L-15 medium (Life Technologies) with 3 mM l-glutamine, 2.5 mg/ml gentamycin, 15 mM HEPES (pH 7.4 with NaOH) until experiments.

Electrophysiological Recordings and Data Analysis—One day after mRNA injection, oocytes were placed one at a time in a custom-built chamber (35), perfused with bath solution (in mM, 96 NaCl, 2 KCl, 1.8 BaCl2, and either 5 mM HEPES to pH 7.0, 7.4, 8.5, or 9.2 with NaOH/HCl or 5 mM MES to pH 5.8 with NaOH/HCl) for two-electrode voltage clamp experiments. l-Glutamate (dissolved in bath solution) was applied for ~5 s with 1 min between subsequent applications using a ValveBank 8 perfusion system (AutoMate Scientific). Ivermectin was applied for longer until saturating current response was observed. Oocytes were clamped at ~60 mV, and currents were recorded with microelectrodes filled with 3 M KCl, OC-725C amplifier (Warner Instruments), and Digidata 1550 digitizer (Molecular Devices) at 1 kHz with 200-Hz filtering. Peak current responses to l-glutamate were later analyzed in Clampfit 10 (Molecular Devices) with 10-Hz filtering for illustration. Peak current responses were plotted against glutamate concentration using the four-parameter Hill equation.

Author Contributions—All authors conceptualized the design and developed the methodology. T. L. and V. V. K. performed investigations. T. L. wrote the original draft, and all authors reviewed and edited the manuscript; T. L. performed visualization. T. L. and S. A. P. were responsible for funding acquisition; S. A. P. supervised the study.

References

Arginine Side Chain in Ligand Recognition


Unique Contributions of an Arginine Side Chain to Ligand Recognition in a Glutamate-gated Chloride Channel
Timothy Lynagh, Vitaly V. Komnatnyy and Stephan A. Pless

doi: 10.1074/jbc.M116.772939 originally published online January 17, 2017

Access the most updated version of this article at doi: 10.1074/jbc.M116.772939

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2017/01/17/M116.772939.DC1

This article cites 36 references, 10 of which can be accessed free at http://www.jbc.org/content/292/9/3940.full.html#ref-list-1